Novavax Raised Guidance by Substituting One Sanofi Check for Another

The raise is almost entirely one check

Novavax's third quarter was, on the surface, the best headline it has produced in years. Management lifted its full-year 2026 revenue framework by $145 million to a $400 million midpoint, range $385–415 million, and improved expense guidance by $5 million. The quarterly numbers looked cleaner too: revenue of $68 million versus $70 million a year ago, but a net loss of $31 million against $202 million, a $171 million year-over-year swing that Jim Kelly attributed partly to $126 million of non-cash charges booked in the prior-year period.

The composition of that raise is where the story lives. Of the $145 million, $125 million is the one-time milestone triggered by Sanofi's European Phase III start for its flu/COVID combination vaccine. The other $20 million is small change split in two: $10 million of product and adjuvant supply, and $10 million of deferred royalty revenue tied to SK bioscience and prior sales to the Korean government — a non-cash recognition, not new demand. Kelly was unusually candid about the durability of the supply piece, noting 2026 Matrix-M demand of 55 million doses is "likely up to 15 million higher than our expected future run rate due to order timing" as partners qualify new manufacturing sites.

Strip out the milestone and this remains a company whose revenue base has been hollowed out. The filed numbers tell it plainly: total revenue fell 76% year over year in the June quarter to $57 million, roughly 79% below the 2022 peak, and the price tag on that shrinking base has re-rated hard — price to revenue sits near 3.8x, up sharply year over year.

The milestone that moved, quietly

Here is the tension the press release does not surface. As recently as last November, the tech transfer payment was supposed to land inside the 2026 framework:

the $75 million milestone that we've included in the 2026 adjusted revenue framework relates to completion of manufacturing tech transfer with Sanofi... we believe we're right on track to be able to complete that manufacturing tech transfer by the fourth quarter next year.

By February, the reason for slippage was on the record — “Sanofi made the decision to actually fully realize all of the tech transfer to a U.S. facility. And so as a result, that's just going to extend the time line for the tech transfer.” — Elaine O'Hara, Head of Business Development or similar senior business role · 2026-02-26 Yesterday it was formalized: “While we do expect to include the $75 million Sanofi tech transfer milestone in the third quarter of 2027, we do not expect to provide guidance for Novavax's APA product sales.” — Jim Kelly, Chief Financial Officer · 2026-11-05 Roughly a year of slippage on a payment that was once the backbone of the 2026 framework — and the new tech transfer date lands in a year whose revenue shape management has already signaled will be thinner: R&D reimbursement and Sanofi amortization become "very small contributors" and end during 2027.

The profitability clock has now moved twice. In November 2025, Kelly pushed the "as-early-as" estimate for non-GAAP profitability from 2027 to 2028 after Sanofi said it would approach regulators on its CIC data. Yesterday: “we are updating our non-GAAP profitability timing expectations to align with this new information from our partner” — Jim Kelly, Chief Financial Officer · 2026-11-05 — and the new anchor is a potential U.S. U.S. CIC commercial launch in 2029, which carries a $225 million milestone. That is a real asset. It is also, by the company's own admission, entirely dependent on a partner's public statements rather than anything Novavax controls.

What management stopped saying

The keyword record is instructive. new MTA — a staple of 2025 and early 2026 calls, when four new material transfer agreements were signed in a single stretch — is now a decliner in the company's own momentum history, and this quarter the topic produced boilerplate. Asked twice about conversion of MTA collaborations into paid licenses, Elaine O'Hara offered: “There is a remarkable level of interest. There is a remarkable level of continued exploration of expanding the utility of our Matrix-M across both infectious disease as well as oncology.” — Elaine O'Hara, Head of Alliance Management or Business Development · 2026-11-05 A year ago she was giving analysts a 4-to-6 month preclinical readout window and a 6-to-12 month path to a collaborative license. That specificity is gone. John Jacobs was franker: “Not every MTA will turn to a deal. Not every experiment will be successful, but many of them could be.” — John Jacobs, Chief Executive Officer · 2026-11-05 Honest — but also a signal that the funnel is being managed for optionality, not counted for revenue.

The cost story, by contrast, is genuinely delivered. Combined GAAP R&D and SG&A fell 41% year over year, and the agile operating model target now has sharper edges: $150–200 million of non-GAAP R&D and SG&A by 2028, headcount below half of the first quarter 2026 level, and a greater-than-50% footprint cut that produces non-cash fixed-asset write-offs of up to $35 million in 2027. Free cash flow remains the problem — negative $81 million in the latest reported quarter, an improvement year over year but still a burn — funded off a balance sheet where liabilities run at 120% of assets. Kelly's runway math is explicit: $676 million of cash and receivables, plus the $200 million of near-term Sanofi milestones, carries the company “through and well into 2029” — Jim Kelly, Chief Financial Officer · 2026-11-05, with the legacy APA liabilities retired by the first quarter of 2029. That is a solvency statement, not a growth statement.

The new pitch: data as an asset

What is genuinely new this quarter is the R&D framing. The library of data — decades of Matrix-M work, now explicitly described as core intellectual property to be shared selectively under CDA and through publications — is being positioned as the product. In C. diff, Bob Walker confirmed a lead candidate has been chosen, targeting both toxin and non-toxin antigens, designed to cover over 90% of circulating ribotypes, with mucosal IgA and protection in two animal challenge models; clinic entry as early as 2027. In oncology, Matrix-M is being tested alone and with immunomodulators including TLR agonists, across both off-the-shelf and personalized approaches. The internal language is explicitly probabilistic — Jacobs described "rigorous assessment of market potential, probability of success" — which is the right register for preclinical work but a long way from the Fast Track designation status that made Sanofi's combination programs valuable in the first place.

The tape already reflects some of this ambivalence. Novavax is up about 15% over the last 90 trading days but sits 19.5% below its October 13 high of $12.82 — and that window closes October 28, just before the milestone announcement Jacobs described as landing "last week." Against a full-history drawdown of 96.8% from the 2021 peak, a $1.6 billion market cap is a bet that the Sanofi relationship keeps paying: $125 million now, $75 million mid-2027, $225 million on a U.S. CIC product launch, royalties after. The raise is real. So is the fact that every one of those checks now sits on someone else's calendar.